A developer of cell-free DNA–based genetic tests used in prenatal screening, oncology monitoring, and transplant rejection assessment. The company’s assays, including Panorama for noninvasive prenatal testing and Signatera for personalized cancer monitoring, are used by clinicians to detect genetic ...
5 members of Congress have disclosed 9 trades in Natera, Inc. (NTRA), a Healthcare company. The buy/sell breakdown shows 5 purchases versus 4 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-10-23 | KENNY MARCHANT | buy | $15K – $50K |
| 2025-09-22 | Josh Gottheimer | buy | $1K – $15K |
| 2025-08-22 | Josh Gottheimer | buy | $1K – $15K |
| 2025-07-22 | Josh Gottheimer | sell | $1K – $15K |
| 2024-11-20 | Josh Gottheimer | buy | $1K – $15K |
| 2023-04-10 | Daniel Goldman | sell | $1K – $15K |
| 2023-03-06 | Daniel Goldman | buy | $1K – $15K |
| 2022-11-03 | Rohit Khanna | sell | $1K – $15K |
| 2021-04-20 | William F Hagerty, IV | sell | $1K – $15K |